Abstract:The aim of achieving selectivity in kinase inhibition is a big challenge within the realm of drug discovery, particularly due to the structural similarities between various kinases. Can machine learning be leveraged to overcome this hurdle? Utilizing different fingerprints may indeed lead to improved results. However, is there a single machine-learning approach that can effectively address selectivity across all kinases. In this study, the author collect kinase activity data from PubChem database (January 2023) using Uniprot IDs for each kinase. Each Uniprot ID is associated with its unique dataset, and duplicate points were removed to ensure accuracy. The data was then appended together, and any datasets containing fewer than 120 points were discarded. Each data point was categorized as either Active (1) or Inactive (0) based on the activity data. Two fingerprinting approaches were employed for predictions: MACCS fingerprints and Morgan2 (ECFP2) with a 2048-bit representation. The combined dataset was then divided into two subsets, one featuring imbalance data and another with balanced data. Random Forest and Artificial Neural Network models were applied to both datasets. To evaluate the performance of these models, various metrics were employed, including accuracy, sensitivity, specificity, and area under the curve (AUC). The results showed that Morgan fingerprinting performed slightly better than MACCS fingerprinting. A total of 480 target IDs was produced, with 452 unique IDs identified. On each dataset(balance and imbalance), two models were developed for both fingerprints, resulting in a combined total of 1920 predictions. Interestingly, the imbalance data yielded higher specificity compared to the balanced data. Each model has been deployed and made publicly available at (github.com/phalem/minKLIFSAI). However, the current data on all kinases is not yet sufficient to enable machine learning to reliably discover selective inhibitors

Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening.

Discovery of Novel Focal Adhesion Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approach Based on Multicomplex-Based Pharmacophore and Molecular Docking

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Augmenting Bioactivity by Docking‐Generated Multiple Ligand Poses To Enhance Machine Learning and Pharmacophore Modelling: Discovery of New TTK Inhibitors as Case Study

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Identifying dual leucine zipper kinase (DLK) inhibitors using e-pharamacophore screening and molecular docking

High throughput screening, docking, and molecular dynamics studies to identify potential inhibitors of human calcium/calmodulin-dependent protein kinase IV

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Discovery of new STAT3 inhibitors as anticancer agents using ligand-receptor contact fingerprints and docking-augmented machine learning

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

MinKLIFSAI: a simple machine learning approach toward selective kinase inhibitor

Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies

Pharmacophore-based virtual screening, molecular docking, and molecular dynamics studies for the discovery of novel FLT3 inhibitors

Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation

Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes

Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors

Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4)